June 4th 2025
Sagimet Biosciences reveals denifanstat's promising phase 3 results, offering a novel oral treatment for moderate to severe acne with significant efficacy.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Will telemedicine impact the future of acne care?
August 14th 2020Will the current practice of using telemedicine for acne care have an impact on the future of dermatology? We spoke with Julie Harper, M.D., owner and president of the Dermatology and Skin Cancer Center of Birmingham in Alabama, on the topic.
How has telemedicine impacted patient visits?
August 12th 2020Julie Harper, M.D., owner and president of the Dermatology and Skin Cancer Center of Birmingham in Alabama, discusses how she approaches treating acne via virtual visits after incorporating telemedicine into her practice due to the COVID-19 pandemic.
A ‘biomarker’ of psychiatric adverse effects with isotretinoin?
July 17th 2020While recognizing that a patient’s mental health generally improves with isotretinoin use due to improvement in acne symptoms, clinicians may consider screening for insomnia during the course of treatment, as it may be an indicator for vulnerability to side effects, researchers say.
Researchers encourage reporting on hormone therapy in acne trial demographics
July 16th 2020Many current acne clinical trials do not consider those patients already on hormone therapy, which researchers say may affect therapeutic outcomes. Authors of a recent study encourage this reporting in future studies to help clinicians better assess how the data might represent a practice population.
FDA approves new label for sarecycline
June 29th 2020Almirall announces the U.S. Food and Drug Administration has approved the updated label for their oral antibiotic sarecycline (Seysara) for treatment of acne vulgaris to help promote the appropriate use of the drug to aid in preventing antimicrobial resistance commonly warned when using antibiotics
FDA approves Aleor’s adapalene gel for acne vulgaris
June 26th 2020The U.S. Food and Drug Administration has approved the Abbreviated New Drug Application for topical retinoid adapalene gel USP, 0.3% from Alembic Pharmaceuticals and its joint venture Aleor Dermaceuticals for treatment of acne vulgaris.
Tazarotene topical for acne vulgaris launches in United States
June 25th 2020Tazarotene lotion 0.045% (Arazlo, Ortho Dermatologics) is officially launched in the U.S. following approval by the U.S. Food and Drug Administration in late 2019 for the treatment of acne vulgaris in patients 9 years and older.
Trifarotene cream proves safe, effective for acne vulgaris
May 11th 2020A recent clinical review proves trifarotene 0.005% cream is an effective and safe treatment for acne vulgaris on the face and neck in patients 9 years and older. Currently, the drug is one of four topical retinoid acne treatments available on the market.
Menlo and Cutia enter agreement for topical minocycline products
April 24th 2020Menlo Therapeutics announces its wholly-owned subsidiary Foamix Pharmaceuticals Ltd. is entering a licensing with Cutia Therapeutics for the company’s FDA-approved 4% topical minocycline foam (AMZEEQ, Foamix) for acne vulgaris in pediatric and adult patients.